苦黄颗粒治疗黄疸型病毒性肝炎的临床疗效分析-沈玲

东南大学学报(医学版)JSoutheastUniv(MedSciEdi)2005,Jul;24(4):237O239[](1958-),,,,E-mail:[e-mail]沈玲,赵伟,舒伟平,杨毅军,李定坤,杜建霞,文睿,钟备,白浩,田玉岭(,210003)[]:观察苦黄颗粒剂治疗黄疸型病毒性肝炎的效果及安全性:采用随机对照方法,试验组用苦黄颗粒6g,每天3次;对照组用苦黄注射液30ml,加入5%葡萄糖500ml,静滴,每天1次疗程3周:两组血清总胆红素治疗前后均有显著性差异(P0.05),而两组间无显著性差异(P0.05)两组总胆红素复常率分别为74.72%和79.79%(P0.05)试验组临床痊愈率32.97%,显效率41.75%,有效率19.78%对照组临床痊愈率40.43%,显效率39.36%,有效率10.64%两组间痊愈和显效率比较无统计学差异:苦黄颗粒和苦黄注射液在黄疸型病毒性肝炎的退黄降酶方面疗效相似,无显著性差异[]肝炎,病毒性,人P中药疗法;黄疸P并发症;大黄P治疗应用;苦参P治疗应用;投药,口服[]R282.71;R512.605;R944.27[]A[]1671O6264(2005)04O0237O03,,,19993~2000320029~200212,1对象与方法1.1(1)2000()([1])(2)18~65(3)(4),,(5),(6)35Lmol#L-1(7)18(56[1])(8)1.291,73,18;94,75,19V2=0.054,P0.05,18~3445,42;35~4417,24;45~6529,28:8,74,2,7:6,80,3,51(TBIL:;DBIL:;ALT:;AST:;GLB:)1.3,6g,330ml5%,131两组治疗前各指标比较(€x?s)nc(TBIL)PLmol#L-1c(DBIL)Lmol#L-1ALTPU#L-1ASTPU#L-1Q(GLB)Pg#L-19194.86?65.5648.33?33.27660.36?660.85475.51?540.2445.82?5.2994106.07?72.5161.26?56.29745.44?714.71492.34?714.7138.75?5.34t1.151.980.8740.1881.42P0.050.050.050.050.05#237#1.41.4.1疗效评价标准:,94%,TBIL17.1Lmol#L:,70%~94%TBIL17.1~25.5Lmol#L-1:,TBIL25.6~34.0Lmol#L-1,30%~69%:TBIL,30%1.4.2安全性评价标准1:,2:,,,3:,,4:1.5SAS8.0,t,2结果2.174.72%,79.79%,,22两组治疗效果比较例n9130(32.97)38(41.75)18(19.78)5(5.49)9438(40.43)37(39.36)10(10.64)9(9.57):2.23,(P0.05),;,(P0.05),3两组治疗前后血肝功能及生化指标比较(€x?s)ntPc(TBIL)PLmol#L-19194.86?65.5621.81?33.309.030.0194106.10?72.5121.85?27.4910.860.01c(DBIL)PLmol#L-19148.33?33.279.09?14.8510.770.019461.26?56.2910.20?12.758.850.01ALTPU#L-191660.36?660.8545.55?25.029.2960.0194745.44?714.7173.80?105.469.2970.01ASTPU#L-191475.51?540.2443.51?46.197.970.0194492.34?384.6756.43?67.6311.160.01COGTPU#L-191179.62?190.27159.36?91.430.960.0594184.45?223.49119.17?100.702.760.01ALBP%9145.82?5.2939.92?4.490.1440.059438.75?5.3440.82?5.292.750.01Q(GLB)Pg#L-19132.39?5.6630.85?4.493.520.019432.09?7.5530.47?8.171.460.05CO(COGT)(ALB)GLB(P0.05),(P0.05)2.34()4两组治疗前后组内证候计分比较(€x?s)ntP9126.9?6.06.5?7.521.230.0019425.4?5.34.7?1.8124.680.001t1.871.81p0.050.05#238#东南大学学报(医学版)2005年7月,24(4)2.41,,2.6%3讨论,,,,,,56,,[2]1996,,,,[3],,,,51020g#kg-1()ALTAST,D-ALT,D-,,,1~2h,,,,1,,,,,,[][1].()[Z].1993.88[2].30[J].,2000,10:41.[3],.Ó[J].,1996,7(1):7O11.[]2004O09O07ClinicalcurativeeffectandsafetyofKuhuanggranuleintreatmentofjaundicevirushepatitisSHENLing,ZHAOWei,SHUWei-ping,YANGYi-jun,LIDing-kun,DUJian-xia,WENRui,ZHONGBei,BAIHao,TIANYu-ling(TheSecondHospitalofNanjing,AffiliatedtotheMedicalCollege,SoutheastUniversity,Nanjing210003,China)Abstract:ObjectiveToobservecurativeeffectandsafetyofKuhuanggranuleintreatmentofjaundicevirushepatitis.MethodThepatientswererandomlyassignedintotreatmentgroupandcontrolgroup.Thetreatmentlastedfor3weeks.Pa-tientsintreatmentgroupweregivenoraltakenwithKuhuanggranule6gthriceperday,patientsincontrolgroupwereintrave-nouslyinjectedwith30mlKuhuangdissolvedin500ml5%glucose.ResultsTherewasasignificantdifferenceofserumto-talbilirubinbetweenpre-treatmentandpos-ttreatmentinbothtwogroups,buttherewasnosignificantdifferenceofserumtotalbilirubinbetweentreatmentgroupandcontrolgroup.Serumtotalbilirubinreturnedtonormalbeing74.72%intreatmentgroupand79.79%incontrolgroup.Therewasnosignificantdifferenceofclinicalrecovery,apparenteffectiverateandeffec-tiveratebetweenthetwogroups,whichwere32.97%,41.75%and19.78%respectivelyinthetreatmentgroupand40.43%,39.36%,10.64%inthecontrolgroup.ConclusionTheeffectofjaundiceregressionandtransaminasedepressionofKuhuanggranuleandKuhuanginjectionaresimilarintreatmentofjaundicevirushepatitis.Keywords:hepatitis,viral,humanPZHONGYAOLIAOFA;jaundicePcomplications;RHEUMOFFICINALEPtherapeu-ticuse;administration,oral#239#沈玲,等.苦黄颗粒治疗黄疸型病毒性肝炎的临床疗效分析